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ABSTRACT OF DISSERTATION

TRANSCRIPTOMIC AND CELLULAR RESPONSE TO MECHANICAL
OVERLOAD AND THE UNDERLYING ROLE OF MACROPHAGES IN
EXTRACELLULAR MATRIX REMODELING
The extracellular matrix (ECM) in skeletal muscle plays an integral role in tissue
development, structural support, and force transmission. Upon mechanical loading,
including resistance exercise, which alter muscle fiber contractile activity, size,
orientation and connectivity, remodeling processes must occur that involve both ECM
deposition and degradation. ECM remodeling involves many cell types in muscle, but the
focus of our research was directed towards macrophages, which participate in the early
immune response to damage and loading. We have consistently demonstrated a
significant increase in skeletal muscle macrophage abundance using pan macrophage
markers (CD11b/CD68) and anti-inflammatory markers (CD206/CD163) following
exercise training in both middle aged and older adults. We report that with 14-weeks of
progressive resistance exercise training (PRT) in older adults (>65 years of age), genes
involved in ECM remodeling, including MMP14, a master regulator of ECM turnover,
were the most upregulated, differentially expressed genes among those identified by
RNA-sequencing in muscle biopsies. Following an acute bout of resistance exercise in
humans and mechanical overload in mouse, single cell RNA-sequencing indicated that
muscle macrophages accumulate MMP14 mRNA. In vitro, we identified leukemia
inhibitory factor (LIF), secreted by electrically-stimulate primary human myotubes, as a
contributor to upregulation of MMP14 expression in macrophages. The data presented
identify a novel mechanism by which skeletal muscle and macrophages interact to
promote ECM remodeling in response to mechanical overload.
KEYWORDS: Macrophages, Skeletal Muscle, Mechanical Overload, Extracellular
Matrix Remodeling, Transcriptomics, Single Cell RNA-sequencing
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CHAPTER 1. INTRODUCTION TO SKELETAL MUSCLE MACROPHAGES AND
EXTRACELLULAR MATRIX REMODELING WITH MECHANICAL OVERLOAD

1.1

Skeletal muscle extracellular matrix and regulators of remodeling

The extracellular matrix (ECM) in skeletal muscle plays an integral role in tissue
development, structural support, and force transmission [1]. The ECM normally accounts
for approximately 10% of muscle weight and is organized into three layers: the
endomysium that surrounds individual muscle fibers, the perimysium that divides the
muscle into fascicles, and the epimysium that provides external support to the entire
muscle [2]. The ECM provides three fundamental functions; the first is basic mechanical
support for vessels and nerves; the second is the connective tissue ensures the passive
elastic response of muscle; and the third is force transmission from the muscle fibers not
only to the tendon and subsequent bone via the myotendinous junctions but also via
lateral transmission between neighboring fibers and fascicles within a muscle. The ECM
is predominately composed of type I and III collagens, which are fibrous ECM proteins
that can vary widely in content and alignment between layers and different muscle types
to accommodate function [3]. Within the endomysium, these collagens converge with a
specialized basement membrane that surrounds each muscle fiber. The composition of the
basement membrane consists mainly of type IV collagen, laminin, and fibronectin [4].
The dystrophin associated glycoprotein provides mechanical linkage between the
contractile proteins within the muscle fiber and the interconnected layers of the basement
membrane and intramuscular collagens [5]. ECM turnover is a normal homeostatic
process that is accelerated in response to stress or damage. When mechanical loading and
strain alter muscle fiber contractile activity, size, orientations and connectivity,
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remodeling processes must occur that involve both ECM deposition and degradation.
ECM deposition is regulated by growth factors belonging to the transforming growth
factor beta (TGF-β) superfamily through the phosphorylation of SMAD proteins that
transduce extracellular signals to the nucleus where they activate downstream gene
transcription resulting in collagen production [6]. The degradation of ECM is mediated
primarily by the production of matrix metalloproteinases (MMP), cathepsins and through
the cellular uptake of ECM fragments [7]. Intact fibrillar collagen can only be cleaved by
a subset of MMPs (MMP1, MMP8, MMP13, and MMP14) and by other proteases, such
as cathepsin K [8, 9]. Subsequently, collagen fragments can be further degraded by other
members of the MMP family like MMP2 and MMP9 [10]. Transcriptomic profiling of
skeletal muscle at early time points (days 3 and 7) in response to injury, mechanical
loading, and reloading after periods of disuse, indicate an overrepresentation of genes
related to ECM remodeling that are shared between all three stimuli [11-13]. ECM
remodeling involves many cell types in muscle, but the focus of this dissertation is
macrophages, which participate in the early immune response to damage and loading.
Using resistance training in humans, and a surgical model of mechanical overload of
mouse muscle to induce hypertrophy, the goal was to define macrophage contributions to
ECM remodeling and muscle adaptation in both human and mouse skeletal muscle.
1.2

Macrophage characterization and activation

In addition to the ECM remodeling gene signature, genes related to an immune response
were also overexpressed at early time points in response to mechanical loading, injury
and reloading following disuse [11-13]. Of the immune cells present within skeletal
muscle, the most abundant immune cell type are macrophages [14]. Macrophages are
2

highly plastic and capable of changing their activation states in response to growth
factors (e.g., CSF-1 and GM-CSF) and external cues, such as cytokines, microbes,
microbial products, and other modulators, including nucleotide derivatives, antibody-Fc
receptor stimulation, glucocorticoids, infection, phagocytosis, and potentially any other
entity capable of being recognized by macrophages [15]. However, for many years,
researchers had mainly stratified macrophages by two oversimplified classifications,
derived from in vitro studies. The two classifications were termed classically activated
M1 macrophages and alternatively activated M2 macrophages. Classical or alternative
macrophages were produced by treating macrophage cell cultures with either interferon 
(M1) or interleukin-4 (M2), respectively [16]. The primary distinguishing factor between
the two treatments was the elevation in pro-inflammatory cytokine expression by
classical macrophages or anti-inflammatory cytokine and growth factor expression from
alternative macrophages [16]. Currently, the field of skeletal muscle research more
commonly identifies macrophages based on origin. The lymphocyte antigen 6C (LY6C)
surface marker in mice and chemokine receptor 2 (CCR2) in humans are used to identify
circulating and infiltrating monocyte-derived macrophages [17]. The axis that mediates
macrophage/monocyte recruitment occurs predominantly through CCR2 and chemokine
ligand 2 (CCL2) also referred to as monocyte chemoattractant protein 1 (MCP-1) [18,
19]. Resident macrophage markers include lymphatic vessel endothelial hyaluronan
receptor 1 (LYVE1), mannose receptor 1 (MRC1, CD206), and scavenger receptor
cysteine-rich type 1 protein M130 (CD163), which are also considered to be markers of
M2 macrophages [20, 21]. Previous reports have demonstrated significant perturbations
to muscle adaptations when infiltrating, as well as resident macrophages, are depleted,
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however, the outcomes are generally unique to the stimulus and timepoint [22-24].
Herein we will use a similar nomenclature to describe macrophages and their contribution
to skeletal muscle adaptations with an emphasis on their pro and antifibrotic roles in
ECM remodeling, as well as how the muscle environment influences macrophage
activation states.
1.3

Evidence of macrophage contribution to ECM deposition

One of the earliest studies to demonstrate macrophage-stimulated collagen synthesis in
vivo was with wound healing [25]. Macrophages isolated from the wound site, expressed
transcripts for TGF-1, platelet-derived growth factor alpha (PDGF), and insulin-like
growth factor-1 (IGF-1) [26]. Intriguingly, macrophages from cardiac tissue were
observed to directly contribute to type IV collagen deposition [27]. Macrophages are
often associated with fibrosis in chronic myopathies such Duchenne muscular dystrophy
(DMD) or chronic unresolved injury, and this is thought to be largely regulated through
their interactions with fibrogenic cell lineages within skeletal muscle [28]. The
mechanism by which macrophages promote skeletal muscle fibrosis was eloquently
described by Juban et al., who identified a mechanism where TGF-1 dimerizes and
complexes with latent TGF- binding protein (LTBP) and then interacts with the ECM
[29]. These authors highlighted the necessity for adenosine monophosphate activated
protein kinase (AMPK) activation to induce the expression of LTBP in macrophages
[29]. AMPK has also been identified as an integral regulator of macrophage activation
towards the anti-inflammatory state (see section 1.5). Fibroblasts were necessary for the
activation of latent TGF-1 via their secretion of a series of enzymes including bone
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morphogenetic protein 1 (BMP-1) and MMP14. This complex interplay ultimately
resulted in the stimulation of collagen production in fibrogenic cells [29].
1.4

Evidence of macrophage contribution to ECM degradation

Macrophages can directly affect the rate of ECM degradation by several distinct
mechanisms. Skeletal muscle regeneration studies demonstrated that macrophage-derived
urokinase-type plasminogen activator (PLAU) was necessary for proper injury resolution
[30]. PLAU is necessary for the conversion of plasminogen into active serine proteinase,
plasmin [30]. The plasminogen system is thought to play a major role in the degradation
of ECM through the activation of MMPs in macrophages and other cell types present
within skeletal muscle [31]. To support these findings, ECM solubilization rates were
measured in macrophage cultures with and without plasminogen. The effects of
plasminogen addition to the culture media resulted in a 15-fold increase in solubilization
rates [32]. Several MMPs including MMP3, 8, 9, 12, 13 and 14 were reported to be
expressed by macrophages in smooth muscle and cardiac muscle environments [7]. To
date, MMP9 is the only MMP that has been reported to colocalize to macrophages in
skeletal muscle [33]. With the vast evidence that macrophages express multiple types of
MMPs in tissues outside of skeletal muscle and the advent of single cell RNA-seq
(scRNA-seq), future studies aimed at identifying macrophage MMP expression are
warranted. Targeted studies examining the consequences of macrophage-specific MMP
deletion in vivo with regeneration or loading studies may uncover a fundamental aspect
of macrophages that has been overlooked to date. Another mechanism by which
macrophages may degrade ECM is through the phagocytosis of debris in injured and
degenerating muscle [34]. Binding of collagen fragments to the cellular membrane
5

integrin receptor 21 results in collagen phagocytosis in macrophages in vitro [10].
Macrophage uptake of ECM in muscle has been proposed, but this mechanism of ECM
degradation has never been directly tested in skeletal muscle.
1.5

Adverse effects of macrophage depletion on skeletal muscle adaptations

following damage in mice
Arnold et al., was the first to report that depletion of circulating monocytes at the time of
injury totally prevented muscle regeneration [22]. The use of the diphtheria toxin receptor
(DTR) inducible system allows for temporal deletion of cells in mice with DT injection
with specificity under the control of the human ITGAM (integrin alpha M) promoter
(CD11b), which is considered a pan marker of macrophages, as well as monocytes. When
DT was injected simultaneously with notexin, a form of myotoxin similar to cardiotoxin,
none of the hallmarks of muscle regeneration were detected, and persistence of necrotic
fibers were observed out to day 7 [22]. The authors also attempted to specifically target
intramuscular resident macrophages at a time point following the removal of necrotic
muscle fibers. Injection of DT 7 days after notexin injection resulted in muscle fiber
cross-sectional area (CSA) from the DT-injected muscle 41% smaller than control PBSinjected muscle [22], which they propose is due to the lack of myogenic differentiation of
satellite cells (see below). In a follow up study, Mounier et al., identified AMPK as a
major regulator of macrophage activation state during the latter regeneration periods
(after day 7). Using a macrophage specific AMPK knockout mouse model, authors
demonstrated that muscle fiber CSA was significantly lower 14 days after cardiotoxin
injury in the knockout animals compared to wild type controls [35]. AMPK1 knockout
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mice also showed hindered phagocytic capacity of apoptotic cells and prolonged
inflammatory signaling [35]. Additional macrophage depletion studies in mouse models
of skeletal muscle regeneration using clodronate liposomes (CL), which induces
apoptosis in monocytes and macrophages, corroborated the findings presented in the
DTR studies [23]. Summan et al., reported similar discrepancies in the accumulation of
necrotic fibers, increased fat accumulation and delays or reductions in classical early
inflammatory cytokine signaling [36]. Summan et al., did not however report any
differences in muscle fiber CSA at day 9 following freeze injury, but a follow up study
using CL with a blunt force contusion injury, reported smaller regenerating muscle fibers
at day 14 [23, 36]. In regeneration studies it is evident that macrophages play an
important role in injury resolution via satellite cell activation [22]. Satellite cells, which
are located beneath the basement membrane of muscle fibers, are highly influenced by
macrophage soluble factors. These factors can either promote proliferative states or drive
satellite cell fusion with existing muscle fibers. For instance, following cardiotoxin
injury, infiltrating macrophages were shown to express cytokine C-X-C motif chemokine
10 (CXCL10) by scRNA-seq analysis which promoted the proliferation of satellite cells
in mice [37]. In terms of satellite cell fusion, overexpression of ADAM metallopeptidase
with thrombospondin type 1 motif 1 (ADAMTS1) in macrophages led to a greater
abundance of myonuclei per fiber, presumably due to satellite cell fusion [38]. However,
the significance of macrophages to muscle adaptations under mild or non-injurious
models that induce muscle growth, such as resistance exercise, is less well-defined.

7

1.6

Deficits in muscle growth and regrowth with macrophage depletion in mice

Using synergist ablation (SA), a technique where mechanical overload of the plantaris is
induced by the transection of the gastrocnemius and soleus, CL treatment in mice over 14
days of overload demonstrated only a two-third increase of wet muscle weight observed
in control animals [39]. Similar to muscle regeneration studies, satellite cell abundance
was also significantly lower in CL treated animals compared to control animals [39].
Authors identified IGF-1 as a potential candidate for the discrepancies observed in
muscle mass accrual, however, no differences were observed in the phosphorylation of
mechanistic target of rapamycin complex 1 (mTORC1), a known downstream target of
IGF-1, in skeletal muscle [39]. This observation is of particular interest when relating
hypertrophy to regeneration studies due to previous reports that macrophage specific
deletion of IGF-1 resulted in smaller muscle fibers following cardiotoxin induced injury
[40].
Hindlimb muscle unloading for 10 days followed by reloading for 4 days is a model to
induce dynamic changes in muscle fiber CSA, that are associated with a robust immune
response [41]. Tidball et al., used this model in combination with intraperitoneal
injections of anti-F4/80, which binds a mouse macrophage surface antigen and results in
their apoptosis, to identify whether macrophages play a role in regrowth and tissue repair.
Effective depletion was observed at day 4 which coincided with a significantly smaller
muscle fiber CSA compared to control animals in the soleus [42]. The authors also
showed a greater proportion of fibers with membrane damage at day 4 in the macrophage
depleted animals [42]. Recently, a publication described a mechanism by which resident
macrophages may cloak tissue microlesions to prevent neutrophil-driven inflammatory
8

damage [43]. It is likely that models of reloading, as well as synergist ablation, induce
microlesions following the onset of loading and macrophages may play an important role
in preventing excess tissue damage and preserve tissue homeostasis.
1.7

Macrophages in human skeletal muscle adaptation

Compared to studies of macrophages in response to rodent injury and loading, relatively
few studies have attempted to understand the role of macrophages in human muscle
adaptation to injury or exercise [44-47]. Mackey et al., used forced lengthening
contractions induced by electrical stimulation to produce muscle fiber injury in young
healthy males. Immuno-stained single muscle fibers revealed a repeating pattern of
necrotic and regenerating zones along the length of the same muscle characterized by
extensive macrophage infiltration alongside differentiating myogenic progenitor cells and
myotubes. We have consistently demonstrated a significant increase in macrophage
abundance following exercise training in middle aged and older adults on skeletal muscle
cross-sections using antibodies against both CD11b and CD206 markers [44, 48]. Walton
et al., found several interesting associations between the change in macrophage
abundance and changes in muscle fiber CSA, as well satellite cell abundance, following
12-weeks of cycle training in a cohort of healthy middle-aged adults [44]. Walton et al.,
also identified several ECM related genes (MMP14, SERPINE1, SPARC, ELN, COL5A1,
COL6A1, TGFB1 and LOX) that were all positively and significantly associated with
changes in macrophage abundance following 12-weeks of training. In a recent
publication, Jensen et al., reported a significant increase in macrophage accumulation and
type I collagen expression at day 4 and 7 in healthy older male adults following an acute
bout of resistance exercise [47]. Macrophages appear to be an important facilitator of
9

skeletal muscle ‘growth and we propose to test the hypothesis that ECM remodeling is an
important underlying mechanism.
1.8

Skeletal muscle influence on macrophage activation state

Studies both in vivo and in vitro have demonstrated that macrophages can undergo
dynamic transitions in activation states [29, 34, 49]. Recently, different regulatory
pathways have been associated with macrophage activation states and involve a variety of
molecular mechanisms at the genomic, transcriptomic, and post-transcriptomic levels
(reviewed in [50]). Despite these recent advances, the signaling pathways responsive to
muscle contraction that regulate macrophage activation state remains poorly understood.
One recent study was able to gain insight into this interaction by using a muscle specific
overexpression model in mice and cells in vitro. The overexpression of peroxisome
proliferation activator receptor-γ (PPAR-γ) coactivator -1α (PGC-1α), which is elevated
following exercise, induced the release of secretion phosphoprotein 1 (SPP1) which
promoted an increase in macrophage abundance. In vitro studies demonstrated SPP1
strongly upregulated MCP-1 expression in macrophages, which influenced the
recruitment of other mononuclear cells such as endothelial cells that also express CCR2
[51]. A primary objective of this dissertation is to contribute to this body of literature by
identifying other novel pathways that may alter macrophage activation state to promote
muscle adaptation in response to hypertrophic stimuli.
1.9

Preview of studies presented

In Chapter 2, we performed bulk RNA-sequencing of human skeletal muscle from
healthy older adults before and after 14-weeks of progressive resistance exercise training
10

(PRT) with and without the AMPK agonist, metformin. We hypothesized that AMPK
activation would promote a greater increase in the anti-inflammatory activation states of
macrophages, and in turn create an environment more conducive for skeletal muscle
growth in older adults with PRT. Although metformin had no effect on macrophage
activation state, PRT significantly increased macrophage abundance in both placebo and
metformin treated groups [48]. ECM remodeling was the most overrepresented pathway
in response to PRT regardless of treatment group, which led to a mechanistic exploration
of macrophage function in relation to ECM remodeling in Chapter 3. We were able to
identify a candidate gene, MMP14, that was increased following PRT, previously shown
to positively correlate to the change in macrophage abundance with exercise [44], and
potential molecular pathways regulating MMP14 expression. We used several different in
vivo and in vitro models to explore mechanisms whereby contracting muscle releases
soluble factors that promote macrophage-mediated ECM degradation. Chapter 4
highlights the novelty of our findings with a focus on the understudied crosstalk between
skeletal muscle fibers and macrophages in response to hypertrophic stimuli. This
information will aid future researchers who are keen on targeting macrophages to
promote ECM remodeling and improve skeletal muscle adaptations.
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CHAPTER 2. METFORMIN ALTERS SKELETAL MUSCLE TRANSCRIPTOME ADAPTATIONS
TO RESISTANCE TRAINING IN OLDER ADULTS

2.1

Introduction

Biological aging is characterized by a progressive decline of physiological and metabolic
functions across multiple organ systems. One of the key phenotypes of aging is the loss
of skeletal muscle mass, a condition known as age-associated muscle atrophy or
sarcopenia [52-54]. This is usually accompanied by reduced strength, muscle quality and
mobility, increased risk of frailty and falls, lack of endurance and poor physical
performance [55]. In the western population, >40% of adults over the age of 60 have
difficulties with daily activities such as walking or standing up from a chair etc. and
>30% suffer from some kind of physical disability [56]. After the age of 60, striking
changes occur in muscle physiology, corresponding to a decline in muscle mass and
deterioration of muscle strength by ~2% each year [57]. The pathophysiology of agerelated decline in muscle mass and function is multifactorial, including biological factors
such as hormonal imbalance, neurodegeneration and motor neuron loss, increased
inflammation and circulating cytokines, as well as environmental factors such as physical
inactivity, inadequate nutritional intake and psychosocial factors [55, 56, 58].
Furthermore, age-associated changes in muscle metabolism, such as mitochondrial
dysfunction and insulin resistance, can have severe implications in muscle homeostasis
and regeneration [59, 60]. We have shown that progressive resistance exercise training
(PRT) induces meaningful increases in muscle strength, power, and functional mobility,
however, the hypertrophic response is, on average, reduced in old compared to young,
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especially within men [61]. The hypertrophic response to PRT is also highly variable in
older adults (reviewed in [62]).

The use of pharmacological interventions to augment the effect of PRT on muscle
hypertrophy in the older adults has been proposed [63-66]. The biguanide metformin has
been studied in the context of exercise capacity, quality of life and mood states, and
metabolic adaptations, such as insulin production and clearance, oxidative stress and
cardiometabolic health in older adults with prediabetes and Type II diabetes [67-69].
Metformin has been extensively used since the 1950s, as the first-line treatment against
Type II diabetes and is one of the most commonly prescribed drugs in the world, either as
a monotherapy or in combination with insulin or other anti-hyperglycemic agents [70].
Metformin directly inhibits mitochondrial enzymes including Complex I [71], activates
AMP-activated protein kinase (AMPK) [72], inhibits NF-B signaling and specifically
blunts the secretion of proinflammatory cytokines in macrophages [73, 74]. Due to its
role beyond anti-hyperglycemia in modulating several fundamental pathways disrupted
during chronic diseases and aging, repurposing metformin to treat cardiovascular
diseases, cognitive decline, cancers, neurodegenerative diseases and ultimately, aging as
a whole, has been proposed [75-80].

Two studies have shown that short-term metformin treatment and exercise do not exhibit
synergy, but work in an antagonistic manner, where metformin attenuates the insulin
sensitizing effect of exercise [81, 82]. Metformin has been shown to induce
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physiologically subtle decreases in peak aerobic capacity evidenced by a reduction in
peak oxygen uptake, peak heart rate, peak ventilation, peak respiratory exchange ratio
and exercise duration [83]. However, another study in prediabetic adults concluded that
metformin in combination with aerobic and resistance exercise training lowered
proinsulin concentrations and increased insulin clearance [84]. Recently, Konopka et al
showed in older adults that metformin blunted aerobic exercise training-induced
improvements in cardiorespiratory fitness, insulin sensitivity, and prevented the gain in
muscle mitochondrial respiration capacity [85]. Thus, there may be a complex interplay
between molecular mechanisms of exercise adaptations and pathways affected by
metformin.

We originally undertook the MASTERS Trial to test the hypothesis that metformin would
act synergistically with PRT to reduce the number of exercise non-responders regularly
observed among older adults by reducing muscle inflammation. However, in the
MASTERS Trial, metformin plus PRT inhibited muscle growth after 14 weeks of
training [48]. In vitro, acute metformin treatment of human primary myotubes
undergoing electrical pulse stimulation (exercise mimetic capable of inducing myotube
hypertrophy) had a repressive effect on mTORC1 signaling, and upregulated AMPK
phosphorylation [48]. Thus, metformin’s impairment of cardiorespiratory fitness and
muscle mass gains in physically active older adults must be reconciled with benefits
associated with health span.
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The purpose of this study was to map the muscle transcriptional response to PRT with or
without adjunctive metformin in the MASTERS Trial, to identify potential mechanisms
contributing to the blunted hypertrophic response in older adults [48]. Previously, global
gene expression studies of human skeletal muscle aging have identified mitochondrial
dysfunction, extracellular matrix organization, complement activation and ribosomal
pathways comprising a differentially expressed aging signature [86, 87]. Effects of PRT
on this signature, with and without metformin, may identify new intervention targets that
counteract sarcopenia, and provide information on potential metformin-exercise
interactions in muscle that are relevant to repurposing metformin to treat aging and agerelated disorders.
2.2

Methods

2.2.1

Study Design, Participants and Interventions

The Metformin to Augment Strength Training Effective Response in Seniors
(MASTERS) Trial is a randomized, controlled, double blind trial comparing the effects of
metformin versus placebo during a 14-week progressive resistance exercise training
(PRT) intervention in healthy men and women ≥ 65 years of age. Participants were
recruited at University of Kentucky and University of Alabama at Birmingham, UAB.
The detailed study design [88] and participant characteristics [48] have been published
previously.
Participants were randomized to receive either placebo or metformin for the duration of
the trial. Subjects underwent a two-week drug or placebo wash-in period prior to
beginning PRT. Those who were randomized to metformin were titrated up to the target
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dose by taking 1 tablet per day (850 mg) for 7 days, followed by 2 tablets per day (1700
mg) for the remainder of the trial.
All study subjects underwent 14 weeks of PRT, supervised by trained personnel. We
employed a variable intensity prescription across the three training days each week
(high/low/high) based on the results of our previous dose-response trial which showed
this prescription optimized strength and muscle mass gains in older adults [89]. Vastus
lateralis muscle biopsies were obtained prior to drug initiation and 3 days after the final
bout of training. Primary outcomes of the trial, muscle size and strength, have been
reported [48]. Vastus lateralis muscle biopsies from young individuals matched for body
mass index were obtained through the Center for Muscle Biology at the University of
Kentucky.
2.2.2

Library Preparation

Total RNA was isolated from baseline muscle biopsies in 37 plaPRT and 28 metPRT
participants and from 14-week post-training muscle biopsies in 26 plaPRT and 24
metPRT participants (average age 71 years old). Of these, 24 plaPRT and 23 metPRT
participants had biopsies at both timepoints. Additionally, total RNA was isolated from
muscle biopsies in 21 young healthy donors (average age 24 years old). Approximately
35 mg of muscle was subjected to bead homogenization in Qiazol (Qiagen, Valencia,
CA) and RNA purified using miRNeasy Mini Kits (Qiagen) and stored at -80oC. RNA
content, integrity and purity were determined with a Nanodrop 2000 spectrophotometer
(Thermo Fisher, Waltham, MA) and the 2100 Bioanalyzer (Agilent, Santa Clara, CA). A
minimum RNA Integrity Number (RIN) of 6.5 was set for all samples.
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2.2.3

Sequencing, Preprocessing and Alignment

Total RNA was sequenced at Novogene Corporation, Chula Vista, CA on an Illumina
HiSeq 4000 system, using a standard paired-end 150 bp (PE150) dual indexing protocol.
The two sets of samples (University of Kentucky and University of Alabama), each
containing samples from all timepoints of both placebo and metformin arm as well as
young, were sequenced in different batches that were corrected for in the downstream
analyses. Raw fastq sequence reads were passed through quality control using FastQC
(0.11.4) [90] and the QC results were compiled for all samples using MultiQC (1.7) [91].
Due to adapter contamination, the raw fastq files were trimmed for adapter sequences,
filtered for low quality reads and too short reads, using the default parameters in fastp
(0.19.4) - an all-in-one preprocessing tool for fastq files [92]. After checking for QC
using the same steps as before, RNA-Sequencing by Expectation Maximization- RSEM
(1.3.0) in conjunction with the STAR aligner (2.6.1b) was used to align the raw reads to
the GRCh38 primary assembly build of the reference human genome, with transcript
annotations (gencode.v29.annotation.gtf) downloaded from GENCODE [93-95].
2.2.4

Differential Gene Expression Analysis

All statistical analysis for the gene expression data were carried out using the R statistical
software (R-3.6.0). The raw counts were filtered for low expression using a counts-permillion (cpm) threshold of 0.6 (10/minimum library size) in at least 24 (number of
samples in the smallest group of comparison). Since the principal component analyses
revealed a distinct sequencing batch effect, the raw count data was corrected for it using
batch as a covariate in the generalized linear model in limma (3.4.0) [96]. The corrected
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data using the removeBatchEffect function in limma was deemed to have minimal
sequencing batch effects after a visual inspection of PCA and used for all downstream
analyses. Raw data were normalized using the trimmed mean of M-values (TMM)
normalization. To minimize heteroscedasticity from the count data and incorporate
precision weights to account for the mean-variance relationship, the voom function was
applied on the normalized data [96]. A linear model was fit on the voom-normalized data,
while adjusting for the study arm (placebo vs metformin) and biopsy time (baseline, 14weeks of PRT with treatment and young). Due to the paired nature of the study, the
participant id was used as a blocking variable. Differential gene expression was measured
using an Empirical Bayes statistic in limma for the following comparisons; plaPRT vs
Baseline, metPRT vs Baseline, Young vs Old Baseline, Young vs plaPRT (14 weeks),
and Young vs metPRT (14 weeks). The raw P-values were adjusted for multiple
comparisons using the Benjamini-Hochberg correction. The adjusted P-value threshold of
0.01 was used to characterize statistically significant differentially expressed genes
(DEG).
2.2.5

Pathway Overrepresentation Analysis

Genes that were deemed to be differentially expressed with statistical significance (AdjP <0.01), were exported to ConsensusPathdb (http://cpdb.molgen.mpg.de/CPDB)
database [97]. The pathways interrogated were Reactome, KEGG, Biocarta,
Wikipathways and PharmGKB. A hypergeometric test was run and pathways with a gene
overlap threshold of 10% of all input genes and the p-value cutoff of 0.01 were included
in the output. Duplicated pathways were excluded from the output.
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2.2.6

Data availability statement

The raw RNA-Seq and count data from this experiment will be accessible in the Gene
Expression Omnibus database (GEO Accession code- GSE157585).
2.3

Results

2.3.1

Global gene expression changes in skeletal muscle with placebo + progressive

resistance training (plaPRT) or metformin + progressive resistance training
(metPRT)
Research participants were randomized in a double-blind fashion to placebo or metformin
for 2 weeks followed by 14 weeks of PRT with continued drug treatment. Vastus lateralis
biopsies were obtained at baseline (prior to drug treatment) and at 16 weeks (following
14-weeks of training) [48]. Fourteen weeks of placebo plus PRT (plaPRT) induced
differential expression of 2048 genes (Adj-P <0.01), with 1161 genes upregulated and
887 downregulated (Figure 2.1A). The combination of metformin and PRT (metPRT)
resulted in differential expression of 1435 genes (Adj-P <0.01), with 817 genes
upregulated and 618 downregulated compared to baseline (Figure 2.1B). Principal
component analysis (PCA) demonstrated a clear effect of PRT with a similar shift in the
global gene expression profiles in both treatment groups (Figure 2.1C), with the Venn
diagram illustrating an overlap of 918 genes (Figure 2.1D). The correlation between fold
changes of the 918 common genes between the two groups was 0.97 (P=2.2e-16), with no
genes showing any anticorrelation (Figure 2.1E). Eleven hundred thirty genes were
exclusively altered in plaPRT, while 517 genes were changed only in metPRT. Gene lists
are included in Supplementary Table 2.1. We found no significant change in
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inflammatory pathway gene expression with either plaPRT or metPRT, which argues
against our original hypothesis that metformin and PRT reduce muscle inflammation.
2.3.2

Pathway overrepresentation within differentially expressed genes (DEG)

Both interventions modulated transcripts involved in anabolic cell signaling, extracellular
matrix (ECM) organization, and RNA metabolism pathways, suggesting a conservation
of these processes in response to PRT with metformin. The directionality of changes in
gene expression demonstrate that ECM genes including collagen genes (COL1A1,
COL3A1, COL4A1, COL6A2 etc.), ECM-receptor interaction genes, focal adhesion
genes, and those encoding matrix metallopeptidases (MMP2, MMP11, MMP14) and
laminin subunits were upregulated in both groups in response to training. On the other
hand, genes belonging to mRNA splicing, RNA metabolism and post-transcriptional
processing pathways were mostly downregulated. These included several nuclear
ribonucleoproteins, serine and arginine rich splicing factors, RNA polymerase II subunit
C, as well as pre-mRNA processing factors (Figures 2.2A and B, Supplementary Table
2.2). However, the number of DEG was higher for all pathways in plaPRT than metPRT
(Figure 2.2C).
Of the 517 genes that changed exclusively in the metPRT group, pathway analysis
illustrated an overrepresentation of aging hallmarks including cellular senescence, and
autophagy [98], as well as post-translational modification pathways, specifically
neddylation and ubiquitination (Figure 2.2D, Supplementary Table 2.3). Our previous
work with short-term metformin treatment alone showed improvement in aging-induced
pathways through inhibition of mTORC1 regulated genes in skeletal muscle of older
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adults [99]; however, it is unclear how changes in gene expression observed here in
metPRT might alter the older adult muscle phenotype.
2.3.3

Reversal of the aging skeletal muscle transcriptome with PRT and metformin

In lieu of our findings that metPRT appeared to affect pathways associated with aging,
we performed RNA-sequencing on skeletal muscle biopsies from 21 young individuals
(mean age 24, 11 females, 10 males, Supplementary Table 2.4) under resting conditions
and compared their transcriptome to that of week 0 baseline biopsies from the older adult
trial participants. Our analysis revealed that 4654 DEG were present when comparing
baseline biopsies (Adj-P <0.01) with 2446 upregulated and 2208 downregulated (Figure
2.3A, Supplementary Table 2.5). Following 14 weeks of PRT, the week 16 time point
from plaPRT compared to young demonstrated a dramatic decrease in DEG that were
previously observed at baseline (2898 DEG), with 1089 new DEG apparent following 14
weeks of plaPRT (Figure 2.3B, Supplementary Table 2.5). MetPRT further reduced the
number of DEG compared to young muscle to 2705, however, the number of unique
DEG that were present after 14-weeks of PRT was also lower compared to placebo (837
DEG), which is consistent with our initial findings that metformin blunts the overall
transcriptomic response to PRT (Figure 2.3B, Supplementary Table 2.5). Young vs old
baseline DEG that were lost following PRT in both groups (1483) include RNA splicing
and numerous genes involved in longevity-associated pathways (Figure 2.3C,
Supplementary Table 2.6). After identifying DEG between young and old muscle at
baseline that were no longer differentially expressed at week 16 in both plaPRT and
metPRT, we identified 466 DEG that returned to young expression levels only in
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metPRT. Pathway overrepresentation analysis showed that these genes were largely
involved in metabolism, particularly lipid metabolism (Supplementary Table 2.7).
2.4

Discussion

In this study, we characterized the effect of metformin on the skeletal muscle
transcriptomic response to PRT in older individuals from the MASTERS Trial [48]. Our
results indicate that PRT induces substantial transcriptional changes in skeletal muscle
with upregulation of genes involved in extracellular matrix (ECM) remodeling and
downregulation of mRNA processing genes being the most affected. We also provide
evidence that metformin reduces skeletal muscle adaptations to PRT at the transcriptomic
level, consistent with the decreases in physiological gains in response to PRT in lean
body mass, and thigh muscle mass and area, as we have previously reported in this cohort
[48]. Recently, the complex interaction between metformin and aerobic exercise training
was described, showing that metformin also blunts improvements in physiological
functions and mitochondrial adaptations otherwise promoted by aerobic exercise training
in older adults [85]. Similarly, the present findings suggest that key molecular cues
underlying adaptations to PRT are attenuated by metformin. Nevertheless, we discovered
gene sets differentially regulated by the combination of PRT and metformin that may
promote health benefits separate from PRT-induced muscle hypertrophy.

Skeletal muscle ECM is crucial to force transmission, structural integrity and muscle
stem cell dynamics [4, 100], and ECM remodeling is hypothesized to be critical for
muscle fiber growth [101]. A large number of genes associated with pathways involved
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in ECM composition and reorganization were upregulated in both plaPRT and metPRT
groups, but to a lesser magnitude in metPRT, potentially contributing to the reduced
growth response. Resistance exercise training in middle aged adults has been shown to
upregulate collagens and MMPs [102]. In particular, MMP2 has been shown to be
necessary for skeletal muscle hypertrophy [103]. We found significant up-regulation of
MMP2 mRNA in response to PRT in both groups, suggesting that metformin may not
interfere with this specific effect of PRT that may contribute to muscle remodeling.

Genes belonging to mRNA splicing and post-transcriptional processing pathways were
mostly downregulated in both groups. Aging is accompanied by a dysregulation in the
splicing machinery including a rise in splicing factors, especially the heterogeneous
nuclear ribonucleoproteins (hnRNPs) [104, 105]. We observed a systematic suppression
of multiple hnRNPs and mRNAs encoding RNA processing and splicing factors, with
down regulation of RNA processing pathways more prominent in plaPRT. Several
studies have demonstrated that alternative splicing is highly enriched in energetically
demanding tissues such as muscle and brain [106]. Upregulation of alternative splicing in
skeletal muscle with aging may activate damage-response mechanisms at a time when
energy becomes scarce [105]. Physical activity in older adults was shown to offset the
changes in splicing machinery [107] and although the functional relevance has yet to be
established, this effect may reduce the number of genes that are differentially spliced and
the number of splicing errors that produce non-functional proteins that tend to increase
with age [108].
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To our knowledge only one other study has performed transcriptome analysis using
microarrays to compare the effects of PRT in healthy older subjects to that of young
resting skeletal muscle [109]. This seminal study illustrated that 596 genes were
differentially expressed at baseline between young and old. Following 6 months of
resistance exercise training a total of 179 of the 596 were no longer significantly different
to that of young. Although our DEG lists are much larger, which is likely due to the
greater number of older subjects at baseline between studies (65 vs 25), as well as our
end point (50 vs 14), we did find commonalities between gene lists including cell cycle
inhibitors p21 and p15, as well as many metabolism related genes. Melov S et al. gene
ontology analysis demonstrated that metabolic and mitochondrial function were largely
impacted by aging and that resistance exercise training had a significant effect on
reversing these age-related deficits [109]. Presently, we observed a similar response with
PRT in both cohorts; however, adjunctive metformin further reduced the number of DEG
between young and old, which appeared largely due to metformin’s effects on genes
related to metabolism; pathway overrepresentation indicated a return to young gene
expression patterns related to lipid metabolism preferentially in metPRT. In our primary
findings of the trial, we reported an increase in AMPK/ACC phosphorylation in
metPRT, that may affect lipogenesis [48]. The known inhibition of Complex I by
metformin [71] coupled with the increased energy demand of PRT may have led to
compensatory activation of pathways involved in lipid metabolism that were previously
dysregulated with age at baseline. However, it should be noted that outcomes from the
MASTERS Trial showed that the PRT-induced decreases in low density muscle (which
contains more intramyocellular lipid than normal density muscle) was similar between
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groups, whereas plaPRT gained significantly more normal density muscle area than
metPRT [48]. Thus, the combined effects of metformin and exercise on muscle density
and lipid content require further study.

A few limitations reduce the scope of our interpretation of the data, including the time
between the last bout of exercise and tissue collection (3 days). It is possible that
metformin inhibited mTOR signaling acutely after each exercise bout, impairing growth,
but did not affect the new homeostasis following training. Although we reported downregulation of mTOR-associated pathways in muscle following 6 weeks of metformin
alone in a crossover study design in older adults [110], chronic effects of metformin on
mTOR regulated pathways were less apparent within the context of exercise training.
Another limitation acknowledged in our primary outcomes paper is the lack of a
sedentary control group given metformin for 16 weeks. We attempted to extrapolate
metformin-specific effects, but without a sedentary group, it is not possible to assess
effects due to metformin or the combined effects of PRT + metformin on gene
expression.

In conclusion, the blunted transcriptomic response to PRT in the presence of metformin is
consistent with the blunted muscle hypertrophic growth response reported in the primary
outcome of the MASTERS Trial [48]. However, specific effects of adjunctive metformin
on the muscle transcriptomic response to PRT, separate from those related to muscle
remodeling, may alter age-associated deficits in muscle metabolism to improve function.
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Metformin and PRT have beneficial effects on health that extend well-beyond skeletal
muscle that should be considered. However, a metformin-exercise interaction in muscle
must be defined in more detail to better inform whether metformin for healthy, physically
active older adults is a correct choice.
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Figure 2.1 Metformin blunts the global transcriptomic changes induced by PRT in human
skeletal muscle. A) Volcano plot of 2048 DEG (Adj-P <0.01) with plaPRT between 16
weeks and baseline; B) Volcano plot of 1435 DEG (Adj-P <0.01) with metPRT
intervention between 16 weeks and baseline; C) Principal component analysis on DEG
shared between plaPRT (orange) and metPRT (green) compared to baseline (blue); D)
Venn diagram showing an overlap of DEG common between plaPRT and metPRT vs
baseline; E) Correlation plot between the fold changes of DEG common between plaPRT
and metPRT. DEG, differentially expressed genes; PRT, progressive resistance exercise
training. N=23 metPRT and 24 plaPRT. DEG, differentially expressed genes; PRT,
progressive resistance exercise training.
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Figure 2.2 Pathway overrepresentation analyses on differentially expressed genes (DEG).
A) Pathways overrepresented in plaPRT-induced DEG with the length of the bar
representing the number of DEG (upregulated genes to the right and downregulated genes
to the left); B) Pathways overrepresented in metPRT-induced DEG; C) Common
pathways overrepresented between the plaPRT (orange) and metPRT (green) groups; D)
Pathways overrepresented in the 517 DEG within the metPRT group that do not overlap
with the DEG for the plaPRT group. DEG, differentially expressed genes; PRT,
progressive resistance exercise training.
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Figure 2.3 PRT reverts aging transcriptome towards that of young resting muscle and the
effects of metformin are additive. A) Volcano plot of 4654 DEG (Adj-P <0.01) between
young and old muscle at baseline; B) Number of DEG observed when comparing young
baseline skeletal muscle to old baseline skeletal muscle (4654 DEG) and young baseline
to old 16 weeks with either plaPRT (3987 DEG) or metPRT (3542 DEG). Dark blue
represents DEG common to throughout all time points and yellow represents those
unique to week 16 time point in either plaPRT or metPRT; C) Pathways overrepresented
from those genes common to both groups following 14-weeks of PRT that were no
different from young. DEG, differentially expressed genes; PRT, progressive resistance
exercise training.
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CHAPTER 3. MACROPHAGE CONTRIBUTION TO EXTRACELLULAR MATRIX
REMODELING WITH MECHANICAL OVERLOAD

3.1

Introduction

The extracellular matrix (ECM) in skeletal muscle plays an integral role in tissue
development, structural support, and force transmission [1]. The ECM normally accounts
for approximately 10% of muscle weight and is organized into three layers (epimysium,
perimysium and endomysium) [2]. The ECM is dominated by type I and III collagens,
which are fibrous ECM proteins that can vary widely in content and alignment between
layers and different muscle types to accommodate function. Within the endomysium,
these collagens converge with a specialized basement membrane that surrounds each
muscle fiber. The composition of the basement membrane consists mainly of type IV
collagen, laminin, and fibronectin. Upon mechanical loading and strain, which alter
muscle fiber contractile activity, size, orientation and connectivity, remodeling processes
must occur that involve both ECM deposition and degradation [3]. The degradation of
ECM is mediated primarily by the production of matrix metalloproteinases (MMP),
cathepsins and through the cellular uptake of ECM fragments. Intact fibrillar collagen can
only be cleaved by a subset of MMPs (MMP1, MMP8, MMP13, and MMP14) and by
other proteases, such as cathepsin K [8, 9]. Subsequently, collagen fragments can be
further degraded by other members of the MMP family such as MMP2 and MMP9 [10].
Transcriptomic profiling of skeletal muscle at early time points (days 3 and 7) in response
to injury, mechanical overload, and reloading after periods of disuse, indicate an
overrepresentation of genes related to ECM remodeling that is shared between all three
stimuli [11-13]. ECM remodeling involves many cell types in muscle, but the focus of
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our research was directed towards macrophages, which participate in the early immune
response to tissue damage and mechanical loading. Using resistance training in humans,
and a surgical model of muscle mechanical overload (MOV) in mouse to induce
hypertrophy, the goal was to define macrophage contributions to ECM remodeling and
muscle adaptations.

We have consistently demonstrated a significant increase in skeletal muscle macrophage
abundance using pan markers (CD11b/CD68) and anti-inflammatory markers
(CD206/CD163) following exercise training in both middle-aged and older adults [44,
48]. Walton et al., also identified several ECM related genes (MMP14, SERPINE1,
SPARC, ELN, COL5A1, COL6A1, TGFB1 and LOX) that were all positively and
significantly associated with changes in macrophage abundance following 12-weeks of
cycle training [44]. We recently reported that with 14-weeks of progressive resistance
exercise training (PRT) in older adults (>65 years of age), genes involved in ECM
remodeling, including MMP14, were the most upregulated, differentially expressed genes
among those identified by RNA-seq [137]. MMP14 is a potent membrane-tethered
collagenase that can cleave type I collagen and is also capable of activating other MMPs
(MMP2 and MMP9) from their latent pro-MMP complex [111]. Although very little
evidence exists in terms of macrophage-specific MMP-mediated ECM remodeling during
skeletal muscle regeneration or exercise training, macrophage-derived urokinase-type
plasminogen activator (PLAU), which is an upstream activator of all MMPs, has been
reported to play a significant role in injury resolution following skeletal muscle injury
[112]. In terms of muscle-macrophage crosstalk, we also sought to identify potential
31

secretory factors that may alter macrophage function, beyond recruitment, and may
influence MMP14 expression in macrophages.
Upstream regulators of MMP14 expression include the leukemia inhibitory factor (LIF)
and interleukin 6 (IL6) family of cytokines, a process that was first discovered in human
colorectal cancer cells [113]. LIF is a closely related cousin to IL6 and both display a
similar signaling network that involves the targeted degradation of tumor protein p53
(p53), a known repressor of MMP14 expression [113]. LIF/IL6 function by binding to the
gp130-janus associated kinase (JAK) receptor and stimulating phosphorylation of STAT3
[114]. Phosphorylated STAT3 then translocates to the nucleus where it transcriptionally
induces inhibitor of DNA-binding 1 (ID1). ID1 upregulates the expression of E3
ubiquitin ligase mouse double minute 2 homolog (MDM2), whose key target is p53
[114]. The degradation of p53 enables specificity protein 1 (Sp1) transcription factor to
access the promoter region of MMP14 that was previously blocked by p53 and promote
transcription of MMP14 gene. We hypothesize that MOV induces the expression of
LIF/IL6 from skeletal muscle fibers, which drives MMP14 expression in resident
macrophages and promotes the degradation of type I collagen. We used several different
in vivo and in vitro models to test this hypothesis. Findings from these studies highlight a
novel and understudied crosstalk between skeletal muscle fibers and macrophages with
MOV that may be important for ECM remodeling to promote hypertrophy.
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3.2

Methods

3.2.1

Human subjects and intervention

Data were acquired from the MASTERS trial (NCT02308228), which was conducted to
determine whether metformin could augment the response to 14-weeks of PRT in healthy
older adults, age > 65 years old. Full details of the study protocol, including participant
inclusion/exclusion criteria and the PRT paradigm designed to optimize muscle mass and
strength gains, can be found elsewhere [88]. The trial was conducted at the University of
Kentucky and the University of Alabama at Birmingham, and all participants signed an
informed consent approved by university IRBs prior to study enrollment. 24 participants
from the placebo only group completed the exercise intervention and were included in
this analysis. Muscle biopsies from the vastus lateralis were collected two weeks before
the 14-week PRT program began and then a final biopsy 3 days after their last bout of
exercise.
One participant, age 87 years old, from the placebo group in the MASTERS trial who
responded well to 14-weeks of PRT was recruited for an acute bout of exercise for single
cell RNA-sequencing (scRNA-seq) analysis. The subject was required to provide a
muscle biopsy from the vastus lateralis 24 hours after one session of unilateral knee
extension resistance exercise. Briefly, the subject performed 5 sets of 10 concentric
repetitions at 70% 1 rep maximum.
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3.2.2

Muscle Biopsies

For all MASTERS participants, muscle biopsies were obtained from the vastus lateralis
muscle, under local anesthetic (1% lidocaine), using the percutaneous needle biopsy
technique of Bergström, with 5- 6mm needles and manual suction. For RNA extraction,
35 mg of muscle tissue was snap frozen in liquid nitrogen and stored at -80°C. For
mononuclear cell isolations, approximately 250 mg of tissue was placed in pre-chilled
Ham’s F-10 media with 10% horse serum. For immunohistochemical analysis,
approximately 100 mg of tissue was embedded in tragacanth gum on cork, frozen in
liquid‐nitrogen cooled isopentane, and stored at −80°C
3.2.3

Animals

Mice from a Pax7CreER/+-tdTomatofl/+ strain were used in all in vivo studies as part of an
ongoing study exploring the role of satellite cell communication during MOV. C57BL/6J
mice (obtained from the Jackson Laboratory) were used for macrophage in vitro
experiments. Experiments and animal care were performed in accordance with the
University of Kentucky Institutional Animal Care and Use Committee. All mice were
housed in a temperature- and humidity-controlled room and maintained on a 14:10
light:dark cycle, with standard chow and water ad libitum. All mice were females >4
months old at the time of experimentation.
3.2.4

Synergist ablation surgery-induced mechanical overload (MOV) of muscle

Mice underwent bilateral synergist ablation surgery to induce hypertrophy of the plantaris
muscle, as previously described by our laboratory [101]. Briefly, mice were anesthetized
using 95% oxygen and 5% isoflurane gas, then approximately 1/3 of the lower
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gastrocnemius/soleus complex was removed, careful not to disturb neural or vascular
supply. Sham mice were also anesthetized and a similar incision was made followed by
immediate suture. Following 4 days of MOV, mice were euthanized via lethal dosage of
sodium pentobarbital and cervical dislocation.
3.2.5

Mononuclear cell isolation from skeletal muscle

To isolate mononuclear cells from mouse and human muscle, we used a modified version
of the fluorescent activated cell sorting (FACS) protocol from the Rando laboratory
[115]. After a single cell suspension was made from fresh muscle using collagenase
followed by collagenase and dispase, it was filtered through a 40 µm strainer. Propidium
iodide (PI) was added to gate out dead cells using an iCyt FACS machine (Sony
Biotechnology, Champaign, IL, USA). In mouse, we separated out satellite cells prior to
scRNA-seq, which were identified as Vcam+ (Biolegend, San Diego, CA, USA), and all
other PI- cells were collected. In human, we used the same digestion protocol to generate
a single cell suspension but subsequently used antibodies to identify immune cells, which
were labeled and sorted as CD11b+/CD45+/PI- (Biolegend), and used for scRNA-seq.
3.2.6

Cell Culture

Human myogenic progenitor cells (MPCs) were isolated from the gracilis of two patients
(1 female and 1 male) undergoing anterior cruciate ligament reconstruction (age 3034 years) using a CD56 (Biolegend) antibody for FACS. Cells were passaged 2-3 times
in growth media consisting of Ham’s F-10, 20% fetal bovine serum (FBS, Atlanta
Biological, Minneapolis, MN, USA), 1% penicillin/streptomycin and 10ng/ml basic
fibroblast growth-factor (bFGF, Peprotech, Rocky Hill, NJ, USA). Cells were
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differentiated into myotubes for 5 days using MyoCult differentiation media (DM,
Stemcell Technologies, Vancouver, Canada). On the fifth day, fresh media was added
just prior to electrical pulse stimulation (EPS). Cells were then either stimulated at 12 V,
1 Hz, 2 ms for 24 hr (IonOptix C‐Pace EP, Westwood, MA, USA) or had electrodes
placed in wells with no stimulation (E(+) or E(-)), followed by immediate RNA
extraction using Qiazol (Qiagen, Hilden, Germany). Conditioned media (CM) was pooled
from each 6-well plate and centrifuged at 600xg for 10 min to remove debris and frozen
at -80°C.
Bone marrow derived macrophages (BMDM) were obtained from bone marrow (BM)
precursor cells as previously described [116]. Briefly, total BM was obtained from mice
by flushing femur BM with Dulbecco’s modified eagle’s media (DMEM). Cells were
cultured in DMEM medium with 20% FBS and 10ng/ml colony stimulating factor- 1
(CSF‐1, Stemcell Technologies) for 6 days; CSF-1 free media was added on day 7 for 12
hr. CM from myotubes was incubated with goat anti-human LIF neutralizing antibody
(0.1 g/ml, ThermoFisher, Waltham, MA, USA) or control IgG overnight at 4°C with
gentle agitation and then diluted 1:1 with Myocult DM. The conditioned media was
added on day 7 for 24 hr. Cells were then immediately collected in Qiazol (Qiagen) for
RNA extraction.
3.2.7

DQ collagen type I assay

The fluorogenic DQ collagen was used to directly monitor collagenase activity in vitro.
Briefly, myotube CM from either E(-) or E(+) was added to BMDM seeded in 12-well
plates. 100g/ml of DQ collagen type I (ThermoFisher) was added to 5 different
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conditions; DM only (control), 1:1 CM/DM from E(-) and E(+) myotubes with no
BMDM, and 1:1 CM/DM from E(-) and E(+) myotubes with BMDM. Following 120
min, 200 ul was removed from each well and added to a 96-well flat bottom plate. To
measure the fluorescence intensity, a fluorescence microplate reader equipped with
standard fluorescein filters was used. Digestion products from the DQ collagen were
measured at an absorption maxima of ~495 nm and fluorescence emission maxima of
~515 nm and corrected for background by subtracting the control from the value derived.
3.2.8

Immunohistochemistry

Human skeletal muscle macrophage identification and quantification were performed
according to a detailed and validated method [117]. Briefly, macrophages were identified
by stepwise incubation with antibodies against the pan macrophage marker CD11b (Cell
Sciences, Newburyport, MA, USA) followed by CD206 (R&D Systems, Minneapolis,
MN, USA). Slides were fixed in −20°C acetone and blocking steps were taken to prevent
nonspecific background and cross‐reactivity between amplification reagents. Slides were
incubated with mouse IgG1 anti-CD11b (1:100, Cell Sciences) in 2.5% normal horse
serum (NHS, Vector Laboratories, Burlingame, CA, USA) overnight at 4°C. On the
second day, the sections were rinsed in PBS, followed by incubation with goat antimouse biotin secondary (1:1,000, Jackson ImmunoResearch, West Grove, PA, USA) for
90 min at room temperature, followed by streptavidin-HRP (ThermoFisher) for 1 hr and
then tyramide signal amplification with Alexa Fluor 488 (ThermoFisher) for 15 min.
Sections were placed back in streptavidin/biotin blocking kit (Vector Laboratories) and
2.5% NHS for 1 hr and incubated overnight with goat anti- CD206 (1:200, R&D
Systems) in 2.5% NHS at 4°C. On the fourth day, sections were incubated in rabbit anti37

goat biotinylated secondary antibody (1:1,000, Jackson ImmunoResearch) for 90 min at
room temperature. Streptavidin Alexa Fluor 594 was then added to the section for 1 hr,
followed by nuclei visualization with DAPI.4′,6‐diamidino‐2‐phenylindole (DAPI)
(ThermoFisher). Slides were coverslipped with Vectashield (Vector Laboratories) and
stitched images of whole muscle cross‐sections were acquired with a 20× objective on a
Zeiss upright microscope (Carl Zeiss, Thornwood, NY, USA). The abundance of all
CD11b+CD206+ cells was manually quantified using the event count tool in Zen
software (Carl Zeiss) and normalized to number of fibers per cross-section.
To visualize capillaries, frozen muscle sections were dried and rehydrated for 5 min with
1x phosphate buffered saline (PBS), followed by two 5‐min washes with PBS. Sections
were blocked for 1 hr in 2.5% NHS then incubated for 90 min with a mixture of 2 lectins:
biotinylated Ulex europaeus (1:200, Vector Laboratories) and biotinylated Griffonia
Simplicifolia (1:200, Vector Laboratories), and anti-laminin (1:200, Millipore Sigma, St.
Louis, MO, USA). Sections were then washed and incubated for 1 hr with streptavidin
Alexa Fluor 594 (ThermoFisher) to visualize capillaries and anti‐rabbit Alexa Fluor 488
(ThermoFisher) to visualize laminin to demarcate fiber borders. After 3 final washes, the
slides were coverslipped with Vectashield and imaged. Capillaries were counted
manually and expressed per muscle fiber.
Analysis of satellite cell abundance was performed as follows. After drying, sections
were fixed in −20°C acetone, washed with PBS, incubated with 3% hydrogen peroxide,
and blocked for 1 hr in 2.5% NHS. Satellite cells were labelled by overnight incubation
with anti–paired box 7 (Pax7) (Developmental Studies Hybridoma Bank, Iowa City,
Iowa, USA). Following PBS washes, sections were incubated with biotinylated anti‐
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mouse IgG1 (1:1,000 Jackson ImmunoResearch) for 90 min. Washes were repeated
followed by a 1 hr incubation with streptavidin-HRP (ThermoFisher). Fluorescent
labelling was achieved by incubating with SuperBoost tyramide signal amplification
Alexa Fluor 488 (ThermoFisher) in PBS for 20 min. Primary antibody against laminin
(Millipore Sigma) was added followed by anti‐rabbit Alexa Fluor 594 secondary
antibody (ThermoFisher) to visualize and quantify muscle fibers. Sections were washed,
incubated for 10 min with DAPI to label nuclei, and coverslipped. Whole cross‐section
images were acquired with a 20× objective, satellite cells were identified as
Pax7+/DAPI+ and expressed per fiber. Laminin immuno-stained images were previously
used to determine fiber size [48]. Myonuclear number was determined using rabbit antidystrophin (Abcam) followed by anti-rabbit Alexa Fluor 488 secondary antibody
(ThermoFisher) and DAPI to visualize and quantify nuclei within the dystrophin border.
3.2.9

Gene expression experiments in myotubes and BMDM

For cellular RNA extraction, cells were lysed in Qiazol reagent (Qiagen), and RNA was
extracted using the Zymo MiniPrep kit (Zymo Research, Irvine, CA, USA) with slight
modification; the aqueous phase from Qiazol (Qiagen) combined with 3-bromochloropropane following phase separation was added directly to the spin column. RNA
concentration and quality were assessed via NanoDrop (ThermoFisher) and Bioanalyzer
using Nano chips (Agilent, Santa Clara, CA, USA). For real-time PCR of cells, 10 ng
of complementary DNA (cDNA) was used per reaction, and reactions were performed
using TaqMan chemistry (ThermoFisher) and Taqman probes; LIF- Hs01055668_m1;
Mmp14-Mm00485054_m1; 2-Microglobulin (B2M)- Hs00187842_m1; (B2m)-
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Mm00437762_m1, on a QuantStudio 3 (ThermoFisher) in duplicate with B2M as the
housekeeping gene.
For RNA sequencing (RNA-seq), myotube RNA was prepared as a 250–300 bp
nonstrand-specific library using the NEBNext Ultra RNA Library Prep Kit (NEB)
followed by paired-end sequencing using an Illumina NovaSeq 6000 s4 platform
(Novogene, Sacremento, CA). Mapping to the human - hg38 transcriptome (release 100)
was performed using STAR, data were normalized to counts per million (CPM) add
1.0E-4 per Partek recommendation. Quality was assessed and reads were filtered by
removing reads that contained adapters, reads that contained N > 0.1% (N represents base
that could not be determined), and low-quality reads (quality value of over 50% of bases
of the read ≤20), and differential analysis was performed using Partek Gene set analysis
(GSA) tool with default report options.
3.2.10 Single cell RNA-sequencing (scRNA-seq)
The single cell suspension from human and mouse muscles was cleared of debris, dead
cells, and doublets via FACS, as described above. The pellet was washed and resuspended in PBS with 0.04% bovine serum albumin (BSA, Millipore Sigma) to
minimize ambient RNA and cellular aggregation, in accordance with 10X Genomics
recommendations (10X Genomics, Pleasanton, CA, USA). Cell concentration was
determined via hemocytometer prior to being loaded on the 10X Chromium chip. After
cells were loaded into the 10X Chromium Controller, the Single Cell 3’ reagent kit was
applied according to the manufacturer’s protocol. Libraries were prepared using version
3.0 chemistry and were sequenced on the Illumina NextSeq 500 platform for mouse and
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the Illumina NovaSeq 6000 system for human. The Cell Ranger Single Cell Software
Suite was used to perform sample demultiplexing, barcode processing and single cell 3′
gene counting (http://software.10xgenomics.com/single-cell/overview/ddddome). The
cDNA insert was aligned to an appropriate reference genome using STAR. For mouse
muscle, mm10 transcriptome (release 93) was used. For human muscle, hg 38
transcriptome (release 100) was used. Partek Flow was used for all downstream analysis
from Filtered_Barcode_Matrix.h5 files. For the mouse sham sample; 96.89% of reads
were within cells, the estimated number of cells was 3,006, with a median gene per cell
of 4,007. For the 4-day MOV mouse sample; 99.38% of reads were within cells, the
estimated number of cells was 4,494, with a median genes per cell of 5,449. For the postacute resistance exercise (RE) bout human sample; 81.9% of reads were within cells, the
estimated number of cells was 3,919, with a median genes per cell of 2,248. Filter criteria
included expressed genes (Min: 400, Max: 6,000) and mitochondrial reads percent (Min:
0%, Max: 15.00%). Additional filtering was performed which excluded features where
values were < 1.0 in at least 99.9% of the samples yielding a total of 12,059 genes for
downstream analysis. Samples were normalized using counts per million and log
transformation. Principal component analysis (PCA) was used prior to Uniform Manifold
Approximation and Projection (UMAP) for visual based clustering. All statistical
comparisons were conducted in Partek using GSA.
3.2.11 Statistical Analyses
Results are presented as mean ± SEM. Data were analyzed with GraphPad Prism
software, via a one-way repeated measures ANOVA with Sidak’s correction for multiple
comparisons or an unpaired two-tailed Student’s t-test. Linear regressions employed the
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Pearson product-moment correlation coefficient when the two continuous variables were
normally distributed (including all figures depicting regressions). Significance was set at
a P <0.05. False-discovery rates set to Adj-P <0.05 were implemented for all scRNA-seq
data analyzed.
3.3

RESULTS

3.3.1

The increase in human muscle macrophages following PRT is positively

associated with changes in muscle fiber cross-sectional area (CSA), capillary
density, myonuclear accretion and satellite cell abundance
We previously published data from the MASTERS clinical trial demonstrating an
increase in macrophages, CSA, and satellite cells comparing baseline and post-14-weeks
of PRT biopsies [48]. In the present study, we determined if the change in macrophage
abundance was correlated to changes in the other muscle properties. We found a positive
association between the percent change in macrophage abundance with CSA (r = 0.578, P
<0.005, Figure 3.1A), myonuclear abundance (r = 0.467, P <0.05, Figure 3.1B), satellite
cells (r = 0.421, P <0.05, Figure 3.1C), and capillaries (r = 0.507, P <0.005, Figure 3.1D).
Representative immunohistochemistry images used for quantifications of macrophages
(CD11b and CD206), satellite cells (Pax7), CSA (Laminin) and myonuclear accretion
(Dystrophin/DAPI) and capillaries (Lectin) are shown in Figures 3.2A-D.
Chapter 2 showed that ECM remodeling genes, including MMP14, are increased
following 14-weeks of PRT [137]. Although the change in macrophage abundance was
not correlated to the change in MMP14 expression with PRT, macrophage and MMP14
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mRNA abundance were correlated in the post-PRT biopsy (Figure 3.1E, r = 0.578, P
<0.05).

3.3.2

Human skeletal muscle macrophage scRNA-seq transcriptome changes

following an acute bout of resistance exercise (RE)
We sought to verify that muscle macrophages express MMP14, as well as other MMP
members, and if expression corresponds to any sub-population of macrophages following
a single bout of RE. We recruited one participant from the MASTERS Trial to provide a
muscle biopsy 24 hr after an acute bout of RE that was processed for scRNA-seq. The
muscle biopsy was digested, cells labeled using a combination of CD45, CD11b and PI
for FACS, and immediately processed for scRNA-seq. Our sorting strategy captured a
variety of different immune cell populations including monocytes, natural killer cells, Tcells, in addition to macrophages (Figure 3.3A). Graph-based clustering identified 10
separate clusters (Fig 3.3B), while the macrophage cloud was divided into 5 separate
clusters (Supplementary Table 3.1). In the larger macrophage clusters (1-3), we identified
various genes capable of inducing skeletal muscle remodeling, including MMP14,
TGF1, VEGFA and IGF1 (Figure 3.4A-D). Cluster 1 expressed the highest levels of
IL10, MMP14 and MMP19 (Supplementary Table 3.1). Cluster 2 had the greatest
enrichment for CCL2, whereas cluster 3 was highest for CCR2 (marker of infiltrating
monocyte/macrophage, Supplementary Table 3.1). In analyzing the data, we found that
MMP14 expression was the most abundant MMP transcript expressed by human muscle
macrophages (Supplementary Table 3.1). Based on our published whole muscle RNA-seq
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data (see Chapter 2) that identified MMP14 as significantly elevated following PRT, we
attempted to further explore potential mechanisms regulating Mmp14 expression in mice
using synergist ablation, a model of mechanical overload (MOV) in muscle.

3.3.3

Mouse MOV induced changes in macrophage sub-populations, activation

and MMP14 expression
To gain further insight into the changes that occur with MOV in macrophages, as well as
other resident mononuclear cells, we performed synergist ablation surgery to induce
skeletal muscle hypertrophy of the plantaris. Sham and 4 day MOV mouse plantaris
muscle was enzymatically digested and sorted on all live cells excluding satellite cells
and processed for scRNA-seq analysis. Using well-known cell type-sepcific markers,
scRNA-seq analysis identified fibrogenic adipogenic progenitor cells (FAPs), endothelial
cells, macrophages, T cells, myonuclei and neutrophils for both Sham and MOV samples
(Figures 3.5A and B). The cell type distribution changed dramatically with MOV when
controlling for total cells analyzed per sample (Sham= 2430 cells and MOV= 4098 cells).
The proportion of mononuclear cells per cell type shifted from Sham to MOV as follows;
67.48% → 6.37% FAPs, 19.54% → 4.22% endothelial cells, 10.08% → 54.65%
macrophages, 2.32 → 2.29% T cells, and 0.57% → 32.48% neutrophils (Figure 3.5C).
The robust increase in macrophage proportion, as demonstrated by the re-classification
of macrophages using UMAP (Figure 3.6A), was subjected to unbiased graph-based
clustering (Figure 3.6B). Unbiased cluster analysis of MOV and Sham macrophages
identified 7 clusters (Figure 3.6B, Supplementary Table 3.2) with Sham macrophages
44

clustering separately (cluster 7). The most notable differences observed were the
enrichment of resident macrophage markers in cluster 7 and markers of infiltration in
cluster 4 (Supplementary Table 3.2). When comparing Sham to MOV macrophages, we
observed 2794 differentially expressed genes (DEG) as visualized by volcano plot
(Figure 3.6C). Those genes that demonstrated the most profound upregulation with MOV
were Arg1, Thbs1, Cxcl3, Slpi, Spp1, and Mmp14 (Adj-P <0.05, Supplementary Table
3.2). Genes that were significantly higher in Sham compared to MOV mice were Retnla,
Cd209 (f,d,b and g), Lyz1, Pla2g2d, and Cxcl13 (Adj-P <0.05, Supplementary Table 3.2).
When assessing whether Mmp14 expression was specific to any graph-based cluster
(Figure 3.6D), we observed that cluster 2 and 3 both demonstrated elevated Mmp14
expression (Supplementary Table 3.2); however, visually, Mmp14 mRNA was more
apparent throughout the entire macrophage cloud (Figure 3.6D) than previously observed
with human macrophages 24 hr after the RE bout. Furthermore, tissue inhibitor of
metalloproteinases 2 and 3 (Timp2/3, inhibitors of Mmp14), were significantly decreased
in MOV mice compared to Sham (Supplementary Table 3.2). When assessing Mmp14
expression changes across all cell types, we found that the predominate source of Mmp14
expression was FAPs (Figure 3.6E). However, following 4 days of MOV, we found that
proportionally, macrophages dramatically increased their expression of Mmp14 (Figure
3.6E). The proportion of mononuclear cells expressing >1 Mmp14 from Sham to MOV is
as follows; 98.2% → 14.35% FAPs, 1.61% → 4.72% Endothelial cells, 0.23% → 79.10%
macrophages, 0.00% → 0.07% T cells, and 0.00% → 1.70% neutrophils (Figure 3.6E). If
these findings translate to humans, this might explain why we did not observe a
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correlation between the change in MMP14 and macrophages with PRT but were able to
identify an association at the end of 14-weeks PRT.
In identifying whether Mmp14 expression was derived from newly infiltrating cells
following MOV, we compared Mmp14 mRNA positive macrophages (1 >Mmp14,
Mmp14(+)) vs. Mmp14 mRNA negative macrophages (1 <Mmp14, Mmp14(-)) in the
MOV sample. GSA generated 1517 DEG (Adj-P <0.05, Supplementary Table 3.3)
between Mmp14(+) and Mmp14(-) macrophages. Markers of infiltrating macrophages
(Ccr2 and Ly6c2) were significantly higher in the Mmp14(-) compared to Mmp14(+)
macrophages (Adj-P <0.05, Supplementary Table 3.3).

3.3.4

LIF mediates increases in MMP14 expression in bone marrow derived

macrophages (BMDM) in response to EPS-stimulated myotube conditioned media
(CM)
To gain further insight into the mechanisms regulating Mmp14 expression in vivo, we
used an in vitro exercise mimetic, electrical pulse stimulation (EPS), to induce chronic
myotube contractions for a 24 hr period. Previous research has shown that EPS induces
both myotube hypertrophy [118], as well as increases in cytokine levels [119]. In
attempting to identify muscle-derived cytokines upregulated by muscle contraction, we
performed RNA-seq on two different primary human cell lines comparing EPS
stimulated (E(+)) to non-stimulated control (E(-)) myotubes. Due to the low N, we used
fold change cut-offs of >1.5 and unadjusted P <0.05 to identify potential cytokines that
were upregulated following 24 hr of EPS (Supplemental Table 3.4). We identified LIF as
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one potential cytokine upregulated with E(+), previously reported to induce the
degradation of p53, a repressor of MMP14 [113, 114]. We validated our RNA-seq
findings with real-time PCR in two human cell lines, performed in triplicate (Figure
3.7A, P <0.05). Next, we sought to determine if LIF influenced Mmp14 expression.
Following 24 hr of E(+) or E(-), we collected myotube CM and treated BMDM for 24 hr
using both E(+) and E(-) conditions. In parallel wells, a human anti-LIF neutralizing
antibody (LIFAb+/-) was added to CM prior to treating BMDM. Following 24 hr,
BMDM RNA was collected immediately and real-time PCR was performed using probes
for Mmp14. Treatment of BMDM with E(+)LIFAb(-) CM resulted in a significant
increase in Mmp14 expression compared to E(-)LIFAb(-) CM (Figure 3.7B, P <0.05).
However, in the presence of the anti-LIF neutralizing antibody, E(+)LIFAb(+) CM failed
to induce a significant increase in Mmp14 expression in BMDM cells (Figure 3.7B).
3.3.5

BMDM treated with EPS conditioned media display enhanced type I

collagen degradation
To determine if elevated Mmp14 expression in BMDM by E(+)LIFAb(-) CM results in
collagen degradation, we used an in vitro model to assess type I collagen degradation
using the DQ Collagen 1 assay, which emits fluorescein as collagen is degraded. We first
assessed if myotube CM following E(+) or E(-) induced anysignificant changes above
control DM. We detected very little fluorescein emission when the collagen was treated
with E(+/-) CM alone. BMDMs treated with E(+/-)LIFAb(+/-) showed a significant
increase in fluorescein across all groups compared to E(+/-) CM alone (no cells, Figure
3.8, P <0.0001). However, E(+)LIFAb(-) CM treated BMDM showed a significant
increase in fluorescein above what was observed from E(-)LIFAb(+/-) CM treated
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BMDM, (Figure 3.8, P <0.05). CM treatment with the anti-LIF neutralizing antibody
(E(+)LIFAb(+)), prevented the increased degradation rates observed in E(+)LIFAb(-)
CM treated BMDM (Figure 3.8).
3.4

Discussion

The primary findings of this study demonstrate a novel interaction between skeletal
muscle fibers and macrophages following mechanical overload that may mediate ECM
remodeling, potentially mediated by MMP14. We provide several novel discoveries in
both humans and mice using various modalities to demonstrate the cross-species
conservation of our findings. These experiments were based on our findings, presented in
Chapter 2, that PRT induces substantial transcriptomic changes to ECM remodeling
pathways [137], as well as the association between changes in macrophage abundance
and changes in ECM remodeling genes in response to exercise we reported previously
[44]. At the end of 14-weeks of PRT, we found that macrophage abundance is
significantly correlated to MMP14 mRNA levels. The change in muscle macrophages
with PRT is also positively associate with changes in muscle fiber CSA, satellite cells,
capillaries and myonuclei following 14-weeks of PRT. MMP14 expression increases 1.6fold following 14-weeks of PRT in older adults, with a more robust change in Mmp14
expression observed following 4 days of MOV in mouse macrophages. We also observed
a concomitant decrease in Mmp14 inhibitors (Timp 2 and 3), which addresses the
potential question of whether known inhibitors of MMP14 mitigate this response [120].
MMP14 has been reported to play an important role in myogenesis, angiogenesis, cell
migration and the degradation of collagens [111, 113, 121]. When looking for potential
regulators of Mmp14 expression with MOV, we identified LIF, which has been shown to
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increase with MOV in mice [122]. No mononuclear cell population increased Lif
expression by scRNA-seq, suggesting the higher Lif expression observed in response to
MOV occurred within the myofibers. Therefore, we utilized an in vitro model of RE
(EPS) using human primary myotube cultures to induce LIF expression and treated
BMDM with E(+/-) CM to determine if myotube-derived LIF is capable of promoting
BMDM Mmp14 expression.

Skeletal muscle research aimed at identifying the importance of macrophage
activation/function with exercise has been largely correlative in nature [44, 123, 124]. To
date only one study has directly demonstrated that macrophage recruitment is necessary
for skeletal muscle hypertrophy in mice following MOV [39]. Although we have begun
to understand the mechanisms by which macrophages are recruited from the circulation
via muscle contraction [125], we have little empirical data to support a mechanism for
how MOV may augment resident macrophage activation and promote muscle growth or
remodeling. Our lab has recently demonstrated significant macrophage accretion
following PRT in healthy older adults [48]. We provide further evidence that macrophage
accretion is positively associated with muscle adaptations following PRT such as muscle
hypertrophy, satellite cell proliferation, angiogenesis and myonuclear accretion.
Moreover, this positive relationship between changes in macrophage abundance and
muscle hypertrophy may play a pivotal role in older adults who are susceptible to certain
aspects of anabolic resistance. From our data, it is apparent that not all subjects responded
favorably in terms of growth to 14-weeks of PRT, however, those that displayed the
greatest improvements in CSA also displayed the greatest increase in macrophage
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abundance. The data generated from our scRNA-seq analysis of one healthy older adult
following an acute bout of RE suggests that macrophages may supplement crucial growth
factors such as VEGFA, which we have previously identified as lower in healthy older
adults compared to young [137].

ScRNA-seq is an attractive approach to identify heterogeneity within cell types,
especially macrophages, which have classically been defined in terms of inflammatory vs
anti-inflammatory phenotypes. We did not observe any overt classical inflammatory
macrophage clusters following an acute bout of RE in our one human subject. Interleukin
1b (IL1b) was detected in two clusters, however, those clusters were observed to consist
of cells relegated to the monocyte cluster. The majority of macrophages expressed
resident macrophage markers such as LYVE1, CD206, and CD163 [21]. This is consistent
with our previous immunohistochemical data demonstrating a high degree of overlap
between the pan-markers CD68/CD11b and alternatively activated (M2) markers
CD206/CD163 [117]. When attempting to identify macrophage heterogeneity in mice
following MOV, the most notable differences were driven by a subset expressing markers
of infiltrating macrophages (Ccr2 and Ly6c2), as well as Il1b. However, this cluster
(cluster 4) also expressed high levels of the alternatively activated macrophage marker
chitinase-like 3 (Chil3 or Ym1).

MOV is similar to muscle regeneration in that it is a potent stimulus for macrophage
infiltration [126]. MOV differs from muscle injury models by maintaining muscle fiber
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integrity and therefore requires a more subtle approach to ECM remodeling, not requiring
removal of necrotic fibers and apoptotic cells. The importance of ECM remodeling with
MOV-induced skeletal muscle hypertrophy is thought to be necessary for permitting
myofiber expansion through the remodeling of the basement membrane [103]. In human
studies, a single bout of exercise did not increase skeletal muscle mRNA levels of
MMP14 [127]. However, following 10 days of training, MMP14 expression was
significantly increased, as well as following 14-weeks of PRT [128]. Synergist ablation
MOV in mice has also been shown to increase Mmp14 expression in the whole muscle
[12], and we propose that this is largely driven by the specific increase in Mmp14
expression from macrophages. Another interesting finding is that human monocytes do
not appear to express high levels of MMP14 according to scRNA-seq. In line with this
finding, it appears that in mice Mmp14(+) macrophages express significantly lower levels
of Ccr2 and Ly6c2, markers of infiltrating monocytes, compared to Mmp14(-)
macrophages. These results suggest that infiltrating monocytes/macrophages do not enter
skeletal muscle primed with high levels of MMP14 and instead require distinct cues from
skeletal muscle to upregulate transcription of MMP14.

Exercise-induced myokines (muscle secreted cytokines) are attractive therapeutic targets
due to their ability to induce beneficial effects in other cells, tissues and organs [129].
LIF has previously been described as resistance exercise-induced myokine [130], and
despite being below detection levels in plasma, LIF is believed to exert local effects
following MOV. In addition, LIF knockout mice fail to undergo skeletal muscle
hypertrophy following 21 days of MOV, and although the authors did not provide a
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mechanism by which LIF promotes skeletal muscle hypertrophy [122]. Our results
suggest an important function of LIF that may facilitate the remodeling of the ECM
through effects on macrophages. LIF increased Mmp14 in muscle macrophages, which
we validated in vitro using an anti-LIF neutralizing antibody. The mechanism by which
LIF potentially regulates MMP14 gene expression was first discovered in a HCT116 cell
line (human colorectal cancer cell line), where authors reported an increase in p53
degradation with LIF treatment [114]. In a similar study, IL6 treatment, which is very
homologous to LIF, was used to further describe the mechanism by which p53
degradation enables Sp1 binding to the MMP14 gene promoter in HCT116 cells [113].
Sp1 has been previously characterized as the primary transcription factor responsible for
MMP14 gene expression in humans [131]. This was illustrated using a luciferase reporter
gene driven by the MMP14 promoter, that lacked the Sp1 binding site. This deletion
reduced luciferase activity by 90%, which indicated an essential role for Sp1 in
maintaining MMP14 transcription [131].

Ultimately our focus was to identify how changes in the muscle macrophage
transcriptome with RE/MOV influence ECM remodeling. Despite illustrating enhanced
type I collagen degradation following E(+) CM treatment of BMDM in vitro, further
studies will be needed in vivo using macrophage-specific Mmp14 knockout mice to
assess the physiological impact of macrophage Mmp14 on ECM remodeling. Similarly,
one could also identify the role of Mmp14 in targeting pro-Mmp2 with MOV, as Mmp2
knockout mice fail to grow in response to MOV [103]. This study provides a myriad of
data for those interested in the muscle macrophage response to MOV, and although our
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focus was on ECM remodeling, other relevant pathways such as metabolism and toll-like
receptor signaling were affected by MOV in muscle macrophages. Transgene insertion of
Lif driven by Cd11b promoter has recently been demonstrated to ameliorate Duchene’s
muscle dystrophy in mice [132]. Taking advantage of how macrophages are recruited to
damaged or exercised muscle makes similar approaches highly attractive. Deepening our
understanding of macrophage function will enable future research to manipulate and
potentially enhance these responses to reduce skeletal muscle fibrosis and anabolic
resistance.
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Figure 3.1 In human vastus lateralis, Pearson r correlation analysis demonstrates a
significant association between changes in macrophage abundance and changes in (A)
muscle fiber CSA (r=0.578, p=0.004, N=23), (B) MN (r=0.467, P=0.02, N=23), (C) SC
(r=0.421, P=0.04, N=24), and (D) CAP (r=0.507, P=0.0059, N=24) following 14-weeks
of PRT. (E) Absolute number of macrophages correlates to MMP14 expression at the end
of PRT (r=0.578, P=0.01, N=18). CSA, cross-sectional area; MN, myonuclei; SC,
satellite cells; CAP, capillaries; MMP14, matrix metalloproteinase 14; PRT, progressive
resistance exercise training; FPKM, fragments per kilobase of transcript per million
mapped reads.
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Figure 3.2 Representative images of skeletal muscle immunohistochemistry. (A) Skeletal
muscle macrophages were identified using antibodies against CD11b (green) and CD206
(red); CD11b+/CD206+ cells were counted (white arrows). (B) Satellite cells were
identified using a Pax7 antibody (red) within the laminin border (green); satellite cells
were expressed per fiber. (B) Muscle fiber cross-sectional area was measured using
laminin (green) to outline fiber borders. (C) myonuclei were identified as DAPI+ (blue)
nuclei within the dystrophin border (gold arrows). (D) Capillaries were identified using
antibodies against lectin (pink) with laminin (green) and measured per fiber (yellow
arrows). Scale bar=100m for A, B, and D; scale bar=20m in C.
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Figure 3.3 scRNA-seq of CD11b+/CD45+ sorted cells derived from human vastus
lateralis 24 hr after an acute bout of RE. (A) Classification of cell types using gene
expression markers identified 5 primary cell types; macrophages (blue), monocytes (red),
NK cells (gold) and T cells /B cells (green). (B) Unbiased graph-based clustering
identifies 10 clusters in human skeletal muscle immune cell populations with 5
macrophage sub-clusters. Data represented using UMAP. UMAP, Uniform Manifold
Approximation and Projection; NK cells, natural killer cells; RE, resistance exercise;
scRNA-seq, single cell RNA-sequencing.
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C

D

Figure 3.4 scRNA-seq analysis of (A) MMP14, (B) TGF1, (C) VEGFA, and (D) IGF1
as potential macrophage-derived regulators of ECM remodeling, angiogenesis, muscle
hypertrophy and satellite cell proliferation/fusion. Data represented using UMAP. Scale
bar represents linear expression levels. UMAP, Uniform Manifold Approximation and
Projection; MMP14, matrix metalloproteinase 14; TGF1; transforming growth factor
beta-1; VEGFA, vascular endothelial growth factor A; IGF1, insulin-like growth factor-1;
ECM, extracellular matrix; scRNA-seq, single cell RNA-sequencing.
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C

Figure 3.5 scRNA-seq demonstrates dynamic changes in cell populations following 4
days of mechanical overload (MOV) in mouse plantaris using UMAP. Cell types were
classified as either endothelial cells, myonuclei, fibrogenic adipogenic progenitors
(FAPs), macrophages, neutrophils or T cells under (A) Sham or (B) MOV conditions. (C)
Shift in cell type proportions following 4 days of MOV accounting for the total number
of cells sorted per sample. N=6,528 total cells (Sham= 2,430 cells and MOV=4,098
cells). scRNA-seq, single cell RNA-sequencing; UMAP, Uniform Manifold
Approximation and Projection.
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Figure 3.6 scRNA-seq of mouse macrophage populations under Sham and mechanical
overload (MOV) conditions. (A) UMAP plot of macrophages under Sham conditions
(red) compared to after 4 days of MOV (blue) in mouse plantaris muscle. (B) Unbiased
graph-based clustering of macrophages from both sham and MOV muscles reveals 7 subclusters with Sham clustering separately (pink). (C) Volcano plot demonstrating the
number of differentially expressed genes (DEG) significantly increased (red) or
decreased (green) when comparing MOV vs Sham (Adj-P <0.05). (D) Mmp14 expression
(blue) in macrophages across MOV and Sham samples. N=2,382 (sham=230 and
MOV=2,152). Assessing Mmp14 expression across cell types in Sham and 4 dayoverloaded muscles. (E) Under Sham conditions, FAPs are the predominate source of
Mmp14 expressing cells, however, following MOV macrophages present as the majority
Mmp14 expressing cells. N=2,396 total cells (sham= 870 cells and MOV=1,526 cells).
scRNA-seq, single cell RNA-sequencing; UMAP, Uniform Manifold Approximation and
Projection; Mmp14, matrix metalloproteinase 14; FAPs, fibrogenic adipogenic
progenitors.
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Figure 3.7 BMDM require LIF upregulation in CM from EPS treated myotubes to induce
Mmp14 expression. (A) RNA was isolated from human primary myotubes (MT)
subjected to EPS for 24 hr (E(+)) and from unstimulated MTs (E(-)). LIF mRNA was
quantified by real-time PCR (*P <0.05), using an un-paired students t-test. N=6. (B) CM
from E(+) and E(-) MTs was pre-treated with 0.1 g/ml of human anti-LIF neutralizing
antibody or IgG control antibody (LIFAb(+/-)) followed by incubation with BMDMs for
24 hr. Cells were collected, RNA isolated and Mmp14 expression quantified by real-time
PCR. Data are expressed as mean ± standard deviation. (*P <0.05). N=6. Results are
expressed as fold change from control group; E(-)LIFAb(-), using one-way repeated
measures ANOVA with Sidak’s correction for multiple comparisons. MT, myotubes;
EPS, electrical pulse stimulation; E(+/-), +/- EPS; BMDM, bone marrow derived
macrophages; CM, conditioned media; Mmp14, matrix metalloproteinase 14; LIF,
leukemia inhibitory factor.
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Figure 3.8 Elevated rates of type I collagen degradation in BMDM is influenced by LIF
from E(+) CM. DQ Type I Collagen substrate was used to measure the degradation rates
of BMDM in the presence of myotube conditioned media (MTCM). BMDM had a
significant effect on type I collagen degradation compared to MTCM alone (#P <0.05).
E(+) CM treatment of BMDM (E(+)LIFAb(-)) had a significant effect above that
observed in control group (E(-)LIFAb(-), *P <0.05). All analysis was performed using
one-way repeated measures ANOVA with Sidak’s correction for multiple comparisons.
N=6 per group. (#P <0.05 ) compared to MTCM. *P <0.05 compared to control BMDM
group. BMDM, bone marrow derived macrophages; LIFAb, LIF neutralizing antibody;
E(+/-), +/- EPS; EPS, electrical pulse stimulation; LIF, leukemia inhibitory factor.

62

CHAPTER 4. CONCLUDING REMARKS AND FUTURE DIRECTIONS
4.1

Summary of findings regarding the regulation of ECM with MOV

Progressive resistance exercise training (PRT) is a potent stimulus for a variety of
skeletal muscle adaptations that produce beneficial functional outcomes. To adapt to
mechanical loading, skeletal muscle must undergo changes both within the muscle fiber,
as well as the surrounding extracellular matrix (ECM). While neuronal input drives
muscle activation, the response that ensues is dependent upon a variety of cell types in
addition to myogenic cells. Using a mouse model of resistance exercise, synergist
ablation-induced mechanical overload (MOV), our lab recently published several
findings that suggest potential crosstalk between satellite cells (muscle stem cells) and
fibroblasts that mediate collagen expression, a major component of the ECM, during
MOV [101]. In addition to this, we have also begun to understand how satellite cells
modify the muscle ECM degradation rates through matrix metalloproteinase (MMP)
regulation [133]. From an “Omics” perspective, as highlighted in Chapter 2, it is apparent
that both ECM synthesis and degradation occur during reorganization in order to promote
physiological adaptations to PRT [137]. Our lab has sought to expand our understanding
of other potential relevant mononuclear cells and how they contribute to ECM regulation.
In Chapter 3, we focused on macrophages, due to their increased abundance following
14-weeks of PRT and positive associations with muscle size, capillary density, and
satellite cell activity.
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4.2

Is ECM turnover necessary for skeletal muscle adaptations to MOV?

The fundamental question regarding whether ECM remodeling is necessary for proper
adaptations to PRT/MOV remains unanswered. Despite the considerable research that has
gone into understanding the composition, as well as the regulators of production and
degradation, little is known about how ECM deposition and degradation ultimately
contribute to muscle adaptations with MOV. Skeletal muscle from aged rats has been
shown to produce less contractile force than muscle from young rats, which may
contribute to what many have termed “anabolic resistance” in older adults [134].
However, to directly assess the role of ECM turnover, the utilization of a mouse strain
that synthesizes type I collagen resistant to collagenase cleavage (point mutations in
regions targeted by MMPs that inhibit degradation) would be required [135]. The use of
this mouse model with MOV may inform our understanding of how necessary ECM
turnover is with the remodeling process and how that ultimately affects changes in force
generation, cross-sectional area, capillary number, and satellite cell function in
overloaded/exercised muscle.
4.3

Skeletal muscle and muscle macrophage crosstalk validation in vivo

The data presented in Chapter 3 makes a compelling point that MOV influences
macrophage activation by driving Mmp14 expression through LIF secretion. While we
attempted to demonstrate that this can have a physiological effect on collagen
degradation in vitro, ultimately, the use of an Mmp14 genetic knockout mouse that is
specific to macrophages would still be necessary. The data would provide further
evidence that macrophages do play a major role in ECM remodeling with MOV. If
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defects to the ECM were observed, one would hypothesize that similar to our satellite cell
ablated mice, deficits in muscle hypertrophy would follow.
4.4

Macrophage ablation models to demonstrate global impact with MOV

Ideally, we would have begun our initial endeavors using a macrophage ablation model
similar in approach to our well-published satellite cell ablation model [136, 137]. Skeletal
muscle macrophages are said to be both derived from yolk-sac origin, as well as
throughout the lifespan, via circulating monocytes [124]. In attempting to employ a
diphtheria toxin A mouse crossed to a pan macrophage/monocyte Cre-recombinase
specific driver mouse, many researchers, including ourselves, have been unable to ablate
macrophages in muscle for extended periods (>3 days) or at very minimal effectiveness
[22]. To successfully ablate resident macrophages and inhibit macrophage recruitment,
one would need a proven and effective macrophage depletion strain such as the Cd11bDTR mouse line, which successfully ablates macrophages for up to 3 days before giving
rise to a surge in infiltrating monocytes. This mouse strain would then be crossed to a
Ccr2 knockout mouse that inhibits infiltrating monocytes. Then one would be able to
delete resident macrophages and prohibit reoccupation by infiltrating monocytes for an
extended time. This is necessary for assessing changes in ECM remodeling as excess
ECM accumulation does not present itself acutely with injury or MOV.
4.5

Final Remarks

This work extends the role of macrophages in muscle beyond that of injury and their
canonical roles in inflammatory and anti-inflammatory muscle repair. Whereas in
response to MOV, heterogeneity exists as resident versus newly infiltrated. The muscle
65

environment clearly alters macrophage phenotype and may result in a unique macrophage
population the promotes ECM remodeling.
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